{
    "nct_id": "NCT03642067",
    "official_title": "Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab",
    "inclusion_criteria": "* Age ≥18 years.\n* ECOG performance status 0 or 1\n* Have metastatic or locally advanced microsatellite stable (MSS) colorectal adenocarcinoma.\n* Cohort A: Primary lesion has a composite PD-L1/Mucin (CPM) score ≥ 15%.\n* Cohort B: Primary lesion has a composite PD-L1/Mucin (CPM) score < 15%.\n* Cohort C: Prior surgical resection of primary tumor. Prospective biomarker evaluation not required.\n* Must have received at least one chemotherapy regimen.\n* Patients with the presence of at least one measurable lesion using RECIST 1.1.\n* Patients must have available archival tissue from the surgical resection of their primary tumor.\n* Patient's acceptance of tumor biopsies.\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study - specified laboratory tests.\n* Documented LVEF ≥ 50% - 6 month prior to drug administration.\n* Must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history or evidence of brain metastases. Patients with previously treated brain metastases may participate if they are stable for 4 weeks prior to beginning treatment, have no new or enlarging brain metastases, and are not using steroids for at least 1 week prior to initiation of study treatment.\n* Require any antineoplastic therapy.\n* History of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or anti-Lag-3 antibodies.\n* Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.\n* Had any cytotoxic drug within 4 weeks prior to initiation of study treatment.\n* Hypersensitivity reaction to any monoclonal antibody.\n* Has uncontrolled intercurrent acute or chronic medical illness.\n* Has an active known or suspected autoimmune disease.\n* Has a diagnosis of immunodeficiency.\n* Prior tissue or organ allograft or allogeneic bone marrow transplantation.\n* Requires daily supplemental oxygen\n* History of interstitial lung disease.\n* Requires daily supplemental oxygen.\n* Significant heart disease\n* History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.\n* Infection with HIV or hepatitis B or C at screening.\n* Has an active infection.\n* Unable to have blood drawn.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Woman who are pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}